Referred to the House Committee on Energy and Commerce.

Original title: “HR 9482: Health and Location Data Protection Act of 2026”

Forwarded by Subcommittee to Full Committee by Voice Vote.

Original title: “HR 9389: Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026”

The policy was being formulated following directions from Chief Minister N. Chandrababu Naidu: Health minister Satya Kumar Yadav Expressing concern over the difficulties faced by patients suffering from rare diseases, Satya Kumar said many were confined to beds or wheelchairs and struggled with day-to-day activities.

Original title: “AP To Frame Policy For Rare Disease Patients”

Senator Rick Scott (R-Fla.), chairing ... therapies for the more than 30 million Americans living with a rare disease. Within weeks of those hearings, Makary and Prasad were gone. Two resignations don’t fix a culture. Real advisory committee reform means appointing disease-specific specialists instead of generalists, mandating patient and family representation, and accepting real-world evidence rather than narrow clinical trial models that ... Senator Rick Scott (R-Fla.), chairing the Special Committee on Aging, put the hearing together with Ranking Member Kristen Gillibrand (D-N.Y.). Scott condemned the FDA’s “inconsistent review practices, shifting standards, and redundant data requests” blocking access to safe and effective therapies for the more than 30 million Americans living with a rare disease. Within weeks of those hearings, Makary and Prasad were gone. Two resignations don’t fix a culture. Real advisory committee reform means appointing disease-specific specialists instead of generalists, mandating patient and family representation, and accepting real-world evidence rather than narrow clinical trial models that are ethically indefensible for small populations. FDA advisory committees hinder rare disease treatment approvals, risking patients' lives and rights. These panels of outside experts are supposed to give the agency independent, informed guidance on new treatments — especially experimental and emerging ones. Instead, they have become a bureaucratic layer that slows approvals, lacks transparency, and simply does not benefit the public. For patients fighting rare diseases that are too often fatal, these committees don’t just fall short. They stand in the way. A doctor with broad clinical knowledge can offer something useful on a general medical question. The FDA has been in hot water for over a year — blocking rare disease, cancer, and other treatments from patients who are running out of time. That leadership is now gone.

Original title: “The FDA's Advisory Committees Are Failing Rare Disease Patients – PJ Media”

Referred to the Committee on Foreign Affairs, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HRES 1375: Reaffirming the importance of the United States promoting the safety, health, and well-being of refugees and displaced persons in the United States and around the world.”

Referred to the Committee on Foreign Relations. (text: CR S2897-2899)

Original title: “SRES 775: A resolution reaffirming the importance of the United States promoting the safety, health, and well-being of refugees and displaced persons in the United States and around the world.”

Read twice and referred to the Committee on the Judiciary.

Original title: “S 4670: A bill to amend Kristen's Act to provide for the inclusion of information related to developmental disabilities, Alzheimer's disease, and dementia in alerts issued through the Ashanti Alert communications network, and for other purposes.”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 5444: Medical Laboratory Personnel Shortage Relief Act of 2025”

This final rule with comment period sets forth provisions to strengthen the oversight of Medicare national accrediting organizations by addressing conflicts of interest, establishing consistent standards, processes, and definitions, and updating the validation and performance standards systems. Additionally, this final rule with comment period revises the psychiatric hospital survey process, adds a limitation on terminated deemed providers and suppliers when reentering the program, and provides

Original title: “Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflicts of Interest, and Related Provisions”

This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.

Original title: “Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program”

The U.S. Department of Health and Human Services (HHS), Office of Disease Prevention and Health Promotion (ODPHP) solicits written comments from the public on new objectives to be added to Healthy People 2030 and gather input to refine or expand the existing screen time objectives.

Original title: “Announcement of Solicitation of Written Comments on Proposed Healthy People 2030 Objectives and Request for Information on Screen Time To Inform Healthy People”

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 20, 2026. The document announced the withdrawal of approval of 11 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of March 23, 2026. The document indicated that FDA was withdrawing approval of ANDAs 078022 for propranolol hydrochloride (HCl), extended- release capsule, 60 milligrams (mg), 80 mg, 120 mg, and 160 mg, and 090665 for lidocaine HCl, injectab

Original title: “Masuu Global Solutions LLC, U.S. Agent for Extrovis AG, et al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications; Correction”

In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Original title: “Submission for OMB Review; 30-Day Comment Request; NIH Extramural Harassment Web Form (Office of the Director, Office of Extramural Research)”

Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.

Original title: “Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments: Reuters”

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

Original title: “Medicare drug price rule may target under-the-skin Keytruda and Opdivo”

Crisis preparedness and responseThe Management Board welcomed EMA’s support to African regulators in the context of the Ebola outbreak in the Democratic Republic of Congo and…

Original title: “EMA Management Board: highlights of June 2026 meeting”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Forms FDA 3542a and FDA 3542: Questions and Answers." This draft guidance is intended to answer commonly asked questions regarding Forms FDA 3542a and FDA 3542, and to assist applicants in preparing and submitting these forms to FDA.

Original title: “Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability”